Cannabis Cannabis stocks slide after DEA decides to push back reclassification hearing Rescheduling of the plant in the U.S. is imminent, but we're not quite there yet Rowan DunneAugust 27, 2024
Science and Research DEA sharply increases quantities of psychedelics, cannabinoids for 2024 research Substances being produced at a more rapid rate this year will include psilocybin, DMT and delta-9 THC Rowan DunneJanuary 4, 2024
Legalization DEA proposes hiking Schedule I drug production for medical research After a spike in demand for research, the DEA is proposing increased quotas for controlled substances including MDMA, LSD, psilocybin and cannabis Natalia Buendia CalvilloOctober 18, 2021
Cannabis US DEA suggests big increase of cannabis and psilocybin production for research The agency says it supports research into the substances and it's necessary for the FDA to approve new quotas Kathryn TindaleSeptember 1, 2021
News US DEA set to authorize potent pot production for research With only one approved US university supplying low-quality cannabis for decades, the DEA says it will finally open up licensing Jared GnamMay 18, 2021
Industry update Low-THC weed led to poor results in major PTSD study US researchers seek DEA to permit potent pot production after long-awaited FDA-backed study shows weak weed ineffective at treating PTSD Jared GnamMarch 30, 2021
Enforcement DEA given police-like power to uphold federal law during protests 'Para-military' force might lack de-escalation tactics when dealing with peaceful protestors, says lawyer Michelle GamageJune 5, 2020